Disease Model News Today

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”),...

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 -- Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference –

Find out if you or a loved one is struggling with addiction from our informative articles. Spot the signs early so you can get the help you need.

Cell coding company bit.bio announces an expansion to its product portfolio to accelerate research into neurodegenerative diseases. Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS)

Data presented on human muscle, CNS and immune cells and associated disease models Cells have been developed with the company's opti-oxTM precision cellular reprogramming technology

First neurodegenerative disease model launched from bit.bios new ioDisease Model portfolio.

First neurodegenerative disease model launched from bit.bio's new ioDisease Model portfolio.